Jul 16, 2022 04:24 AM

TECH

Genuine Biotech Reports Unimpressive Results for Covid Pill

By Qi Zhanning and Han Wei

China’s domestic drugmakers are rushing to develop their own Covid treatments.

China’s domestic drugmakers are rushing to develop their own Covid treatments.

Chinese drugmaker Genuine Biotech reported unimpressive trial results for its Azvudine Covid treatment, prompting a sell-off in related drug stocks.

The response reflected concerns that Azvudine’s clinical trial results fell short of regulatory recommendations. While privately held Genuine Biotech said the drug improved clinical symptoms, Chinese regulators in a February guideline said Covid-19 treatments should reduce severe illness and death.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Pests on the Plateau

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin-Sinica Business Brief: China’s First Homegrown Jet Sets Sights on Airbus and Boeing

00:00

00:00/00:00

MOST POPULAR

1: Cover Story: China’s Tobacco Monopoly Is Swept Up in Corruption Probes

2: China’s Factory Activity Gets Back to Growth, but Recovery Remains Patchy, Caixin PMI Shows

3: China’s EV Industry Calls on Regulators to Curb the Back-Seat Driving

4: Weekend Long Read: Five Tasks for China’s Next Stage of Opening-Up

5: In Depth: China’s Proposed New Curbs on Private Securities Funds Spark Controversy

SPONSORED

OR